vs
Amphastar Pharmaceuticals, Inc.（AMPH）とBALCHEM CORP（BCPC）の財務データ比較。上の社名をクリックして会社を切り替えられます
BALCHEM CORPの直近四半期売上が大きい（$270.7M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.5倍）。BALCHEM CORPの純利益率が高く（14.9% vs 13.3%、差は1.5%）。BALCHEM CORPの前年同期比売上増加率が高い（8.1% vs -1.8%）。BALCHEM CORPの直近四半期フリーキャッシュフローが多い（$33.8M vs $24.6M）。過去8四半期でBALCHEM CORPの売上複合成長率が高い（7.5% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
バルケムコーポレーションはグローバルな特殊化学品・栄養原料サプライヤーで、人用栄養、動物保健、医薬品、工業用途の4分野を中心に、用途に応じた高品質な製品を北米、欧州、アジア太平洋地域の顧客に提供している。
AMPH vs BCPC — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $270.7M |
| 純利益 | $24.4M | $40.3M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 20.5% |
| 純利益率 | 13.3% | 14.9% |
| 売上前年比 | -1.8% | 8.1% |
| 純利益前年比 | -35.7% | 8.7% |
| EPS（希薄化後） | $0.51 | $1.25 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $270.7M | ||
| Q4 25 | $183.1M | $263.6M | ||
| Q3 25 | $191.8M | $267.6M | ||
| Q2 25 | $174.4M | $255.5M | ||
| Q1 25 | $170.5M | $250.5M | ||
| Q4 24 | $186.5M | $240.0M | ||
| Q3 24 | $191.2M | $239.9M | ||
| Q2 24 | $182.4M | $234.1M |
| Q1 26 | — | $40.3M | ||
| Q4 25 | $24.4M | $39.2M | ||
| Q3 25 | $17.4M | $40.3M | ||
| Q2 25 | $31.0M | $38.3M | ||
| Q1 25 | $25.3M | $37.1M | ||
| Q4 24 | $38.0M | $33.6M | ||
| Q3 24 | $40.4M | $33.8M | ||
| Q2 24 | $37.9M | $32.1M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | 35.6% | ||
| Q3 25 | 51.4% | 35.7% | ||
| Q2 25 | 49.6% | 36.4% | ||
| Q1 25 | 50.0% | 35.2% | ||
| Q4 24 | 46.5% | 36.0% | ||
| Q3 24 | 53.3% | 35.6% | ||
| Q2 24 | 52.2% | 35.5% |
| Q1 26 | — | 20.5% | ||
| Q4 25 | 19.4% | 19.8% | ||
| Q3 25 | 13.2% | 20.4% | ||
| Q2 25 | 24.2% | 20.1% | ||
| Q1 25 | 21.9% | 20.4% | ||
| Q4 24 | 24.2% | 19.8% | ||
| Q3 24 | 29.8% | 20.0% | ||
| Q2 24 | 30.3% | 19.6% |
| Q1 26 | — | 14.9% | ||
| Q4 25 | 13.3% | 14.9% | ||
| Q3 25 | 9.0% | 15.1% | ||
| Q2 25 | 17.8% | 15.0% | ||
| Q1 25 | 14.8% | 14.8% | ||
| Q4 24 | 20.4% | 14.0% | ||
| Q3 24 | 21.1% | 14.1% | ||
| Q2 24 | 20.8% | 13.7% |
| Q1 26 | — | $1.25 | ||
| Q4 25 | $0.51 | $1.21 | ||
| Q3 25 | $0.37 | $1.24 | ||
| Q2 25 | $0.64 | $1.17 | ||
| Q1 25 | $0.51 | $1.13 | ||
| Q4 24 | $0.74 | $1.03 | ||
| Q3 24 | $0.78 | $1.03 | ||
| Q2 24 | $0.73 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $72.9M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $1.3B |
| 総資産 | $1.6B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $72.9M | ||
| Q4 25 | $282.8M | $74.6M | ||
| Q3 25 | $276.2M | $65.1M | ||
| Q2 25 | $231.8M | $65.4M | ||
| Q1 25 | $236.9M | $49.9M | ||
| Q4 24 | $221.6M | $49.5M | ||
| Q3 24 | $250.5M | $73.7M | ||
| Q2 24 | $217.8M | $63.7M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $788.8M | $1.3B | ||
| Q3 25 | $776.7M | $1.3B | ||
| Q2 25 | $757.5M | $1.3B | ||
| Q1 25 | $751.3M | $1.2B | ||
| Q4 24 | $732.3M | $1.1B | ||
| Q3 24 | $727.7M | $1.2B | ||
| Q2 24 | $713.3M | $1.1B |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $40.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $33.8M |
| FCFマージンFCF / 売上 | 13.4% | 12.5% |
| 設備投資強度設備投資 / 売上 | 4.5% | 2.3% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 0.99× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $40.1M | ||
| Q4 25 | $32.9M | $67.3M | ||
| Q3 25 | $52.6M | $65.6M | ||
| Q2 25 | $35.6M | $47.3M | ||
| Q1 25 | $35.1M | $36.5M | ||
| Q4 24 | $29.0M | $52.3M | ||
| Q3 24 | $60.0M | $51.3M | ||
| Q2 24 | $69.1M | $45.0M |
| Q1 26 | — | $33.8M | ||
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — |
| Q1 26 | — | 12.5% | ||
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — |
| Q1 26 | — | 0.99× | ||
| Q4 25 | 1.35× | 1.72× | ||
| Q3 25 | 3.03× | 1.63× | ||
| Q2 25 | 1.15× | 1.23× | ||
| Q1 25 | 1.39× | 0.98× | ||
| Q4 24 | 0.76× | 1.56× | ||
| Q3 24 | 1.48× | 1.52× | ||
| Q2 24 | 1.82× | 1.40× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
BCPC
セグメントデータなし
